Dimethylformamide → (R)-2-(1-(8-cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)-1H-imidazol-4-yl)acetonitrile

HRID 44832

반응식

HRID 44832 반응식
[NH:1]1[CH:5]=[C:4]([CH2:6][C:7]#[N:8])[N:3]=[CH:2]1.CN[C@@H]1[CH2:16][CH2:15][CH2:14][CH2:13][C@H:12]1[NH:17][CH3:18].C([O-])([O-])=O.[Cs+].[Cs+].[CH3:25][N:26]([CH:28]=[O:29])[CH3:27]>>[CH:12]1([N:17]2[C:18]3[N:3]=[C:2]([N:1]4[CH:5]=[C:4]([CH2:6][C:7]#[N:8])[N:3]=[CH:2]4)[N:1]=[CH:5][C:25]=3[N:26]([CH3:27])[C:28](=[O:29])[C@H:4]2[CH2:6][CH3:7])[CH2:13][CH2:14][CH2:15][CH2:16]1

참가 물질

5

반응 조건

온도
110 °C

실험 절차

A mixture of intermediate B (150 mg, 0.509 mmol), 2-(1H-imidazol-4-yl)acetonitrile (1.01 mmol, 2 equivalents, 108 mg), Cut (0.1 equivalents, 0.0509 mmol, 10 mg), trans-1,2 bis(methylamino)cyclohexane (14 mg, 0.102 mmol) and Cs2CO3 (1.01 mmol, 331 mg) in DMF (1 mL) was purged with nitrogen and was subsequently heated in a sealed vial at 110° C. for 18 h. The reaction was diluted with ethyl acetate, filtered through Celite and evaporated. The residue was purified by reverse phase preparative HPLC and lyophilized to give the title compound (185 mg). 1H NMR (CDCl3) δ: 8.66 (s, 1H), 7.91 (s, 1H), 7.76 (s, 1H), 4.31-4.37 (m, 2H), 3.91 (s, 2H), 3.38 (s, 3H), 1.70-2.13 (m, 10H), and 0.93 ppm (t, J=7.4 Hz, 3H); LCMS: 366.1 m/z (M+H)+; ret. Time: 3.444 min (Analytical Method A).

후처리

  1. customwas purged with nitrogen
  2. additionThe reaction was diluted with ethyl acetate
  3. filtrationfiltered through Celite
  4. customevaporated
  5. customThe residue was purified by reverse phase preparative HPLC

출처 및 근거

ORD 기록
ord-8cc89f87399b4b3e82cd973d4487ed03
출처 데이터셋
uspto-grants-2013_09
특허 번호
US08541418B2

연결된 노트

불러오는 중…